{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:26:27Z","timestamp":1759692387552},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,2,24]],"date-time":"2010-02-24T00:00:00Z","timestamp":1266969600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Womens Ment Health"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s00737-010-0150-x","type":"journal-article","created":{"date-parts":[[2010,2,23]],"date-time":"2010-02-23T14:11:46Z","timestamp":1266934306000},"page":"443-447","source":"Crossref","is-referenced-by-count":7,"title":["Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature"],"prefix":"10.1007","volume":"13","author":[{"given":"Murat","family":"Kuloglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Okan","family":"Ekinci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yakup","family":"Albayrak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Caykoylu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,2,24]]},"reference":[{"key":"150_CR1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.brainres.2003.09.082","volume":"1003","author":"K Aihara","year":"2004","unstructured":"Aihara K, Shimada J, Miwa T et al (2004) The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Res 1003:9\u201317","journal-title":"Brain Res"},{"key":"150_CR2","volume-title":"Diagnostic and statistical manual of mental disorders text rev","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders text rev, 4th edn. American Psychiatric Association Press, Washington, DC","edition":"4"},{"key":"150_CR3","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.4088\/JCP.v65n0918f","volume":"65","author":"I Anghelescu","year":"2004","unstructured":"Anghelescu I, Wolf J (2004) Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report. J Clin Psychiatry 65:1286\u20131287","journal-title":"J Clin Psychiatry"},{"key":"150_CR4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","volume":"302","author":"KD Burris","year":"2002","unstructured":"Burris KD, Molski TF, Xu C et al (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. Pharmacol Exp Ther 302:381\u2013389","journal-title":"Pharmacol Exp Ther"},{"key":"150_CR5","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.schres.2008.09.019","volume":"107","author":"MJ Byerly","year":"2009","unstructured":"Byerly MJ, Marcus RN, Tran QV et al (2009) Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res 107:218\u2013222","journal-title":"Schizophr Res"},{"key":"150_CR6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","volume":"166","author":"DE Casey","year":"2003","unstructured":"Casey DE, Carson WH, Saha AR et al (2003) Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 166:391\u2013399","journal-title":"Psychopharmacology (Berl)"},{"key":"150_CR7","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.pnpbp.2007.11.007","volume":"32","author":"CH Chen","year":"2008","unstructured":"Chen CH, Huang MC, Lu ML (2008) Aripiprazole resolves symptomatic hyperprolactinemia in a male schizophrenic patient. Prog Neuropsychopharmacol Biol Psychiatry 32:893\u2013894","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"150_CR8","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","volume":"64","author":"PM Haddad","year":"2004","unstructured":"Haddad PM, Wieck A (2004) Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64:2291\u20132314","journal-title":"Drugs"},{"key":"150_CR9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","volume":"441","author":"S Jordan","year":"2002","unstructured":"Jordan S, Koprivica V, Chen R et al (2002) The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441:137\u2013140","journal-title":"Eur J Pharmacol"},{"key":"150_CR10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261\u2013276","journal-title":"Schizophr Bull"},{"key":"150_CR11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/YIC.0b013e32832c25d7","volume":"24","author":"CY Kim","year":"2009","unstructured":"Kim CY, Chung S, Lee JN et al (2009) A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol 24:181\u2013188","journal-title":"Int Clin Psychopharmacol"},{"key":"150_CR12","doi-asserted-by":"crossref","first-page":"833","DOI":"10.4088\/JCP.v61n1105","volume":"61","author":"BJ Kinon","year":"2000","unstructured":"Kinon BJ, Basson BR, Gilmore JA et al (2000) Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry 61:833\u2013840","journal-title":"J Clin Psychiatry"},{"key":"150_CR13","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.pnpbp.2006.02.001","volume":"30","author":"BH Lee","year":"2006","unstructured":"Lee BH, Kim YK, Park SH (2006) Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 30:714\u2013717","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"150_CR14","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/JCP.0b013e31814f4d5d","volume":"27","author":"RA Lorenz","year":"2007","unstructured":"Lorenz RA, Weinstein B (2007) Resolution of haloperidol-induced hyperprolactinemia with aripiprazole. J Clin Psychopharmacol 27:524\u2013525","journal-title":"J Clin Psychopharmacol"},{"key":"150_CR15","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.pnpbp.2008.09.016","volume":"32","author":"ML Lu","year":"2008","unstructured":"Lu ML, Shen WW, Chen CH (2008) Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 32:1978\u20131981","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"150_CR16","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1176\/appi.ajp.2007.06091479","volume":"164","author":"D Mamo","year":"2007","unstructured":"Mamo D, Graff A, Mizrahi R et al (2007) Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 164:1411\u20131417","journal-title":"Am J Psychiatry"},{"key":"150_CR17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-9964(03)00050-1","volume":"61","author":"SR Marder","year":"2003","unstructured":"Marder SR, McQuade RD, Stock E et al (2003) Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61:123\u2013136","journal-title":"Schizophr Res"},{"key":"150_CR18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/0269881107082901","volume":"22","author":"A Mir","year":"2008","unstructured":"Mir A, Shivakumar K, Williamson RJ et al (2008) Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol 22:244\u2013253","journal-title":"J Psychopharmacol"},{"key":"150_CR19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.euroneuro.2008.02.004","volume":"18","author":"AL Montejo","year":"2008","unstructured":"Montejo AL (2008) Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol 18:108\u2013114","journal-title":"Eur Neuropsychopharmacol"},{"key":"150_CR20","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799\u2013812","journal-title":"Psychol Rep"},{"key":"150_CR21","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.euroneuro.2009.04.002","volume":"19","author":"CU Pae","year":"2009","unstructured":"Pae CU, Serretti A, Chiesa A et al (2009) Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. Eur Neuropsychopharmacol 19:562\u2013570","journal-title":"Eur Neuropsychopharmacol"},{"key":"150_CR22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1017\/S1461145706007115","volume":"10","author":"M Paulzen","year":"2007","unstructured":"Paulzen M, Gr\u00fcnder G (2007) Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole. Int J Neuropsychopharmacol 10:149\u2013151","journal-title":"Int J Neuropsychopharmacol"},{"key":"150_CR23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00004850-200015060-00005","volume":"15","author":"J Peuskens","year":"2000","unstructured":"Peuskens J (2000) Switching approach in the management of schizophrenia patients. Int Clin Psychopharmacol 15:15\u201319","journal-title":"Int Clin Psychopharmacol"},{"key":"150_CR24","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","volume":"60","author":"SG Potkin","year":"2003","unstructured":"Potkin SG, Saha AR, Kujawa MJ et al (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:681\u2013690","journal-title":"Arch Gen Psychiatry"},{"key":"150_CR25","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S1461145706006523","volume":"10","author":"M Raja","year":"2007","unstructured":"Raja M (2007) Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole. Int J Neuropsychopharmacol 10:107\u2013110","journal-title":"Int J Neuropsychopharmacol"},{"key":"150_CR26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00004850-200401000-00009","volume":"19","author":"S Ramaswamy","year":"2004","unstructured":"Ramaswamy S, Vijay D, William M et al (2004) Aripiprazole possibly worsens psychosis. Int Clin Psychopharmacol 19:45\u201348","journal-title":"Int Clin Psychopharmacol"},{"key":"150_CR27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.schres.2005.01.009","volume":"76","author":"G Remington","year":"2005","unstructured":"Remington G, Chue P, Stip E et al (2005) The crossover approach to switching antipsychotics: what is the evidence? Schizophr Res 76:267\u2013272","journal-title":"Schizophr Res"},{"key":"150_CR28","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","volume":"164","author":"JC Shim","year":"2007","unstructured":"Shim JC, Shin JG, Kelly DL et al (2007) Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 164:1404\u20131410","journal-title":"Am J Psychiatry"},{"key":"150_CR29","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1592\/phco.26.6.748","volume":"26","author":"A Szarfman","year":"2006","unstructured":"Szarfman A, Tonning JM, Levine JG et al (2006) Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 26:748\u2013758","journal-title":"Pharmacotherapy"},{"key":"150_CR30","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1176\/appi.ajp.162.8.1542-a","volume":"162","author":"R Wahl","year":"2005","unstructured":"Wahl R, Ostroff R (2005) Reversal of symptomatic hyperprolactinemia by aripiprazole. Am J Psychiatry 162:1542\u20131543","journal-title":"Am J Psychiatry"},{"key":"150_CR31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4088\/JCP.0607e14","volume":"68","author":"PJ Weiden","year":"2007","unstructured":"Weiden PJ, Buckley PF (2007) Reducing the burden of side effects during long-term antipsychotic therapy: the role of \u201cswitching\u201d medications. J Clin Psychiatry 68:14\u201323","journal-title":"J Clin Psychiatry"},{"key":"150_CR32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2710.2007.00806.x","volume":"32","author":"J Wolf","year":"2007","unstructured":"Wolf J, Fiedler U (2007) Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole. J Clin Pharm Ther 32:197\u2013198","journal-title":"J Clin Pharm Ther"}],"container-title":["Archives of Women's Mental Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00737-010-0150-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00737-010-0150-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00737-010-0150-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T05:45:49Z","timestamp":1559108749000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00737-010-0150-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,24]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["150"],"URL":"https:\/\/doi.org\/10.1007\/s00737-010-0150-x","relation":{},"ISSN":["1434-1816","1435-1102"],"issn-type":[{"value":"1434-1816","type":"print"},{"value":"1435-1102","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,24]]}}}